HC Wainwright & Co. analyst Joseph Pantginis reiterates IMV (NASDAQ:IMV) with a Buy, 1-for-10 reverse stock
Purple Biotech Reports New Preclinical Data On Potential Of NT219 To Re-sensitize Resistant Tumors To Immune Checkpoint Inhibitors
New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023
REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE)
